Full Coverage

Bristol-Myers, Pfizer report phase 2 dose-ranging study results - Quick Facts

                   
pharmiweb.co.uk
02-Sep-2008
        
Story Timeline:  93 days

9/2/2008 5:19 AM ET (RTTNews) - Bristol-Myers Squibb Co. (BMY: News ) and Pfizer Inc (PFE: News ) Tuesday reported the results of a Phase 2 dose-ranging study involving the investigational compound apixaban in patients with acute coronary syndrome, commonly known as heart attack or severe chest pain. The APPRAISE-1 study compared the current standard of care for acute coronary syndrome, or ACS, including aspirin... [read full story]                    

Add Comment
Latest article on this story:

Bristol-Myers and Pfizer report encouraging results for Phase II ACS trial

 pharmaceutical-business-review.com 05-Sep-2008
First article on this story:

New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome...

 businesswire.com 02-Sep-2008
Selected publications with coverage of this story:
pharmaceutical-business-review.com wsbt.com medicalnewstoday.com pharmiweb.co.uk medpagetoday.com businesswire.com
RELATED
Found 2 documents:
                   

ESC: Experimental Anticoagulant Shows Promise in Phase II Study

medpagetoday.com
04-Sep-2008
        

MUNICH, Sept. 4 -- Apixaban, a Factor Xa inhibitor, may reduce ischemic events among patients with acute coronary syndrome, but bleeding is an issue, researchers said here. "The net clinical benefit of apixaban appears...

Pfizer, Bristol - Myers say apixaban increased bleeding but may reduce acute coronary symptoms

pharmiweb.co.uk
02-Sep-2008
        

NEW YORK (AP) - Pfizer Inc. and Bristol-Myers Squibb Co. said Tuesday a midstage safety study showed their experimental blood thinner apixaban did increase patients' risk of bleeding, but may also reduce patients' risk...